Low-dose aspirin in polycythaemia vera: A pilot study

T. Barbui; G. de Gaetano; G. Finazzi; Raffaele Landolfi; R. Marchioli; C. Patrono; G. Tognoni; F. Capani; A. De Carli; D. Gambi; G. G. Nenci; S. Tura; F. Mandelli; P. Rossi-Ferrini; T. Barbui; S. Cortelazzo; G. Finazzi; O. Vestri; S. Tura; C. Finelli; F. Nocentini; E. M. Pogliani; I. R. Miccolis; B. Bizzi; B. Rocca; R. Tartagilione; G. Angeli; A. Di Blasio; A. Di Pasquale; V. Kramer; R. M. Marfisi; M. Olivieri; L. Sciulli; R. Spoltore; F. Mandelli; E. Montefusco; A. Spadea; M. Carotenuto; M. Nobile; A. Morelli; L. Resegotti; M. A. Ciocca Vasino; F. Rodeghiero; M. Ruggeri; Gruppo Italiano Studio Policitemia (GISP)

doi:10.1046/j.1365-2141.1997.362682.x

Low-dose aspirin in polycythaemia vera: A pilot study

T. Barbui, G. de Gaetano, G. Finazzi, Raffaele Landolfi, R. Marchioli, C. Patrono, G. Tognoni, F. Capani, A. De Carli, D. Gambi, G. G. Nenci, S. Tura, F. Mandelli, P. Rossi-Ferrini, T. Barbui, S. Cortelazzo, G. Finazzi, O. Vestri, S. Tura, C. FinelliF. Nocentini, E. M. Pogliani, I. R. Miccolis, B. Bizzi, B. Rocca, R. Tartagilione, G. Angeli, A. Di Blasio, A. Di Pasquale, V. Kramer, R. M. Marfisi, M. Olivieri, L. Sciulli, R. Spoltore, F. Mandelli, E. Montefusco, A. Spadea, M. Carotenuto, M. Nobile, A. Morelli, L. Resegotti, M. A. Ciocca Vasino, F. Rodeghiero, M. Ruggeri, Gruppo Italiano Studio Policitemia (GISP)

Research output: Contribution to journal › Article › peer-review

Abstract

In this pilot study, aimed at exploring the feasibility of a large-scale trial of low-dose aspirin in polycythaemia vera (PV), 112 PV patients (42 females, 70 males, aged 17-80 years) were selected for not having a clear indication for, or contraindication to, aspirin treatment and randomized to receive oral aspirin (40 mg/d) or placebo. Follow-up duration was 16 ± 6 months. Measurements of thromboxane A₂ production during whole blood clotting demonstrated complete inhibition of platelet cyclooxygenase activity in patients receiving aspirin. Aspirin administration was not associated with any bleeding complication. Within the limitations of the small sample size, this study indicates that a biochemically effective regimen of antiplatelet therapy is well tolerated in patients with polycythaemia vera and that a large-scale placebo-controlled trial is feasible.

Original language	English
Pages (from-to)	453-456
Number of pages	4
Journal	British Journal of Haematology
Volume	97
Issue number	2
DOIs	https://doi.org/10.1046/j.1365-2141.1997.362682.x
Publication status	Published - 1997

Keywords

Antiplatelet treatment
Aspirin
Polycythaemia vera
Randomized clinical trial
Thromboxane

ASJC Scopus subject areas

Medicine(all)
Hematology

Access to Document

10.1046/j.1365-2141.1997.362682.x

Cite this

Barbui, T., de Gaetano, G., Finazzi, G., Landolfi, R., Marchioli, R., Patrono, C., Tognoni, G., Capani, F., De Carli, A., Gambi, D., Nenci, G. G., Tura, S., Mandelli, F., Rossi-Ferrini, P., Barbui, T., Cortelazzo, S., Finazzi, G., Vestri, O., Tura, S., ... Gruppo Italiano Studio Policitemia (GISP) (1997). Low-dose aspirin in polycythaemia vera: A pilot study. British Journal of Haematology, 97(2), 453-456. https://doi.org/10.1046/j.1365-2141.1997.362682.x

Barbui, T, de Gaetano, G, Finazzi, G, Landolfi, R, Marchioli, R, Patrono, C, Tognoni, G, Capani, F, De Carli, A, Gambi, D, Nenci, GG, Tura, S, Mandelli, F, Rossi-Ferrini, P, Barbui, T, Cortelazzo, S, Finazzi, G, Vestri, O, Tura, S, Finelli, C, Nocentini, F, Pogliani, EM, Miccolis, IR, Bizzi, B, Rocca, B, Tartagilione, R, Angeli, G, Di Blasio, A, Di Pasquale, A, Kramer, V, Marfisi, RM, Olivieri, M, Sciulli, L, Spoltore, R, Mandelli, F, Montefusco, E, Spadea, A, Carotenuto, M, Nobile, M, Morelli, A, Resegotti, L, Ciocca Vasino, MA, Rodeghiero, F, Ruggeri, M & Gruppo Italiano Studio Policitemia (GISP) 1997, 'Low-dose aspirin in polycythaemia vera: A pilot study', British Journal of Haematology, vol. 97, no. 2, pp. 453-456. https://doi.org/10.1046/j.1365-2141.1997.362682.x

@article{8b4bb1e07ff34c168b8338ceb4701f97,

title = "Low-dose aspirin in polycythaemia vera: A pilot study",

abstract = "In this pilot study, aimed at exploring the feasibility of a large-scale trial of low-dose aspirin in polycythaemia vera (PV), 112 PV patients (42 females, 70 males, aged 17-80 years) were selected for not having a clear indication for, or contraindication to, aspirin treatment and randomized to receive oral aspirin (40 mg/d) or placebo. Follow-up duration was 16 ± 6 months. Measurements of thromboxane A2 production during whole blood clotting demonstrated complete inhibition of platelet cyclooxygenase activity in patients receiving aspirin. Aspirin administration was not associated with any bleeding complication. Within the limitations of the small sample size, this study indicates that a biochemically effective regimen of antiplatelet therapy is well tolerated in patients with polycythaemia vera and that a large-scale placebo-controlled trial is feasible.",

keywords = "Antiplatelet treatment, Aspirin, Polycythaemia vera, Randomized clinical trial, Thromboxane",

author = "T. Barbui and {de Gaetano}, G. and G. Finazzi and Raffaele Landolfi and R. Marchioli and C. Patrono and G. Tognoni and F. Capani and {De Carli}, A. and D. Gambi and Nenci, {G. G.} and S. Tura and F. Mandelli and P. Rossi-Ferrini and T. Barbui and S. Cortelazzo and G. Finazzi and O. Vestri and S. Tura and C. Finelli and F. Nocentini and Pogliani, {E. M.} and Miccolis, {I. R.} and B. Bizzi and B. Rocca and R. Tartagilione and G. Angeli and {Di Blasio}, A. and {Di Pasquale}, A. and V. Kramer and Marfisi, {R. M.} and M. Olivieri and L. Sciulli and R. Spoltore and F. Mandelli and E. Montefusco and A. Spadea and M. Carotenuto and M. Nobile and A. Morelli and L. Resegotti and {Ciocca Vasino}, {M. A.} and F. Rodeghiero and M. Ruggeri and {Gruppo Italiano Studio Policitemia (GISP)}",

year = "1997",

doi = "10.1046/j.1365-2141.1997.362682.x",

language = "English",

volume = "97",

pages = "453--456",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley & Sons, Ltd (10.1111)",

number = "2",

}

TY - JOUR

T1 - Low-dose aspirin in polycythaemia vera

T2 - A pilot study

AU - Barbui, T.

AU - de Gaetano, G.

AU - Finazzi, G.

AU - Landolfi, Raffaele

AU - Marchioli, R.

AU - Patrono, C.

AU - Tognoni, G.

AU - Capani, F.

AU - De Carli, A.

AU - Gambi, D.

AU - Nenci, G. G.

AU - Tura, S.

AU - Mandelli, F.

AU - Rossi-Ferrini, P.

AU - Barbui, T.

AU - Cortelazzo, S.

AU - Finazzi, G.

AU - Vestri, O.

AU - Tura, S.

AU - Finelli, C.

AU - Nocentini, F.

AU - Pogliani, E. M.

AU - Miccolis, I. R.

AU - Bizzi, B.

AU - Rocca, B.

AU - Tartagilione, R.

AU - Angeli, G.

AU - Di Blasio, A.

AU - Di Pasquale, A.

AU - Kramer, V.

AU - Marfisi, R. M.

AU - Olivieri, M.

AU - Sciulli, L.

AU - Spoltore, R.

AU - Mandelli, F.

AU - Montefusco, E.

AU - Spadea, A.

AU - Carotenuto, M.

AU - Nobile, M.

AU - Morelli, A.

AU - Resegotti, L.

AU - Ciocca Vasino, M. A.

AU - Rodeghiero, F.

AU - Ruggeri, M.

AU - Gruppo Italiano Studio Policitemia (GISP)

PY - 1997

Y1 - 1997

N2 - In this pilot study, aimed at exploring the feasibility of a large-scale trial of low-dose aspirin in polycythaemia vera (PV), 112 PV patients (42 females, 70 males, aged 17-80 years) were selected for not having a clear indication for, or contraindication to, aspirin treatment and randomized to receive oral aspirin (40 mg/d) or placebo. Follow-up duration was 16 ± 6 months. Measurements of thromboxane A2 production during whole blood clotting demonstrated complete inhibition of platelet cyclooxygenase activity in patients receiving aspirin. Aspirin administration was not associated with any bleeding complication. Within the limitations of the small sample size, this study indicates that a biochemically effective regimen of antiplatelet therapy is well tolerated in patients with polycythaemia vera and that a large-scale placebo-controlled trial is feasible.

AB - In this pilot study, aimed at exploring the feasibility of a large-scale trial of low-dose aspirin in polycythaemia vera (PV), 112 PV patients (42 females, 70 males, aged 17-80 years) were selected for not having a clear indication for, or contraindication to, aspirin treatment and randomized to receive oral aspirin (40 mg/d) or placebo. Follow-up duration was 16 ± 6 months. Measurements of thromboxane A2 production during whole blood clotting demonstrated complete inhibition of platelet cyclooxygenase activity in patients receiving aspirin. Aspirin administration was not associated with any bleeding complication. Within the limitations of the small sample size, this study indicates that a biochemically effective regimen of antiplatelet therapy is well tolerated in patients with polycythaemia vera and that a large-scale placebo-controlled trial is feasible.

KW - Antiplatelet treatment

KW - Aspirin

KW - Polycythaemia vera

KW - Randomized clinical trial

KW - Thromboxane

UR - http://www.scopus.com/inward/record.url?scp=84983134916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983134916&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1997.362682.x

DO - 10.1046/j.1365-2141.1997.362682.x

M3 - Article

C2 - 9163613

VL - 97

SP - 453

EP - 456

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -

Low-dose aspirin in polycythaemia vera: A pilot study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this